The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
To own CoreCivic, you have to believe its government detention and corrections contracts will remain durable enough to support earnings, even as policy and ESG scrutiny evolve. The decision to redeem the remaining US$238,468,000 of 4.750% senior notes due 2027 early improves balance sheet flexibility, but does not materially change the key near term catalyst of facility activations or the central risk around concentrated federal funding and contract renewals.
Among recent announcements, the April 10, 2026 US$100 million Incremental Term Loan and expanded US$800 million credit facility are most relevant to this redemption. Together, they show CoreCivic actively reshaping its capital structure while funding facility ramp ups and the Clinical Solutions Pharmacy acquisition, which ties directly into the core catalyst of converting idle or underutilized assets and new service platforms into higher occupancy, revenue and margins.
Yet against this improving balance sheet, investors should still weigh the risk that any shift in ICE or U.S. Marshals funding and detention policies could...
Read the full narrative on CoreCivic (it's free!)
CoreCivic's narrative projects $3.0 billion revenue and $236.6 million earnings by 2029. This requires 8.8% yearly revenue growth and about a $107.3 million earnings increase from $129.3 million today.
Uncover how CoreCivic's forecasts yield a $36.40 fair value, a 13% upside to its current price.
The most bullish analysts already expected revenue of about US$3.1 billion and earnings near US$246 million by 2029, which is far more optimistic than consensus and could look different once this debt redemption and the risk of higher leverage from new loans and acquisitions are fully reflected.
Explore 3 other fair value estimates on CoreCivic - why the stock might be worth less than half the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com